# Westinghouse Air Brake Technologies Corp: financial statements, quarterly WAB · NYSE · CIK 943452 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/wab.md) · [Financials](/companies/wab/financials.md) · [Filings](/companies/wab/filings.md) · [Insiders](/companies/wab/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/wab/financials.md?period=annual). ## Income statement | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [2,526 d](/filings/0001628280-26-008067.md) | [2,497](/filings/0001628280-25-019005.md) | [2,644](/filings/0001628280-25-035852.md) | [2,663](/filings/0001628280-25-045790.md) | [2,583 d](/filings/0001628280-26-008067.md) | [2,610](/filings/0001628280-26-026422.md) | [2,706](/filings/0001628280-26-049139.md) | [2,886](/filings/0001628280-26-066629.md) | [2,965 d](/filings/0001628280-26-008067.md) | [2,950](/filings/0001628280-26-026422.md) | [3,179](/filings/0001628280-26-049139.md) | [3,120](/filings/0001628280-26-066629.md) | | Cost of revenue | $m | [1,762 d](/filings/0001628280-26-008067.md) | [1,682](/filings/0001628280-25-019005.md) | [1,770](/filings/0001628280-25-035852.md) | [1,783](/filings/0001628280-25-045790.md) | [1,786 d](/filings/0001628280-26-008067.md) | [1,710](/filings/0001628280-26-026422.md) | [1,768](/filings/0001628280-26-049139.md) | [1,884](/filings/0001628280-26-066629.md) | [1,999 d](/filings/0001628280-26-008067.md) | [1,889](/filings/0001628280-26-026422.md) | [2,018](/filings/0001628280-26-049139.md) | [1,956](/filings/0001628280-26-066629.md) | | Gross profit | $m | [764 d](/filings/0001628280-26-008067.md) | [815](/filings/0001628280-25-019005.md) | [874](/filings/0001628280-25-035852.md) | [880](/filings/0001628280-25-045790.md) | [797 d](/filings/0001628280-26-008067.md) | [900](/filings/0001628280-26-026422.md) | [938](/filings/0001628280-26-049139.md) | [1,002](/filings/0001628280-26-066629.md) | [966 d](/filings/0001628280-26-008067.md) | [1,061](/filings/0001628280-26-026422.md) | [1,161](/filings/0001628280-26-049139.md) | [1,164](/filings/0001628280-26-066629.md) | | Research and development | $m | [61.0 d](/filings/0001628280-26-008067.md) | [48.0](/filings/0001628280-25-019005.md) | [57.0](/filings/0001628280-25-035852.md) | [50.0](/filings/0001628280-25-045790.md) | [51.0 d](/filings/0001628280-26-008067.md) | [46.0](/filings/0001628280-26-026422.md) | [50.0](/filings/0001628280-26-049139.md) | [59.0](/filings/0001628280-26-066629.md) | [68.0 d](/filings/0001628280-26-008067.md) | [56.0](/filings/0001628280-26-026422.md) | [70.0](/filings/0001628280-26-049139.md) | [67.0](/filings/0001628280-26-066629.md) | | Selling, general and administrative | $m | [296 d](/filings/0001628280-26-008067.md) | [281](/filings/0001628280-25-019005.md) | [316](/filings/0001628280-25-035852.md) | [318](/filings/0001628280-25-045790.md) | [333 d](/filings/0001628280-26-008067.md) | [307](/filings/0001628280-26-026422.md) | [347](/filings/0001628280-26-049139.md) | [375](/filings/0001628280-26-066629.md) | [461 d](/filings/0001628280-26-008067.md) | [401](/filings/0001628280-26-026422.md) | [400](/filings/0001628280-26-049139.md) | [383](/filings/0001628280-26-066629.md) | | Operating income | $m | [308 d](/filings/0001628280-26-008067.md) | [412](/filings/0001628280-25-019005.md) | [430](/filings/0001628280-25-035852.md) | [433](/filings/0001628280-25-045790.md) | [334 d](/filings/0001628280-26-008067.md) | [474](/filings/0001628280-26-026422.md) | [472](/filings/0001628280-26-049139.md) | [491](/filings/0001628280-26-066629.md) | [356 d](/filings/0001628280-26-008067.md) | [517](/filings/0001628280-26-026422.md) | [600](/filings/0001628280-26-049139.md) | [625](/filings/0001628280-26-066629.md) | | Interest expense | $m | not reported | [47.0](/filings/0001628280-25-019005.md) | [49.0](/filings/0001628280-25-035852.md) | [52.0](/filings/0001628280-25-045790.md) | [53.0 d](/filings/0001628280-26-008067.md) | [46.0](/filings/0001628280-26-026422.md) | [46.0](/filings/0001628280-26-049139.md) | [65.0](/filings/0001628280-26-066629.md) | [68.0 d](/filings/0001628280-26-008067.md) | [71.0](/filings/0001628280-26-026422.md) | [80.0](/filings/0001628280-26-049139.md) | [80.0](/filings/0001628280-26-066629.md) | | Income tax | $m | [63.0 d](/filings/0001628280-26-008067.md) | [86.0](/filings/0001628280-25-019005.md) | [94.0](/filings/0001628280-25-035852.md) | [92.0](/filings/0001628280-25-045790.md) | [71.0 d](/filings/0001628280-26-008067.md) | [99.0](/filings/0001628280-26-026422.md) | [111](/filings/0001628280-26-049139.md) | [112](/filings/0001628280-26-066629.md) | [87.0 d](/filings/0001628280-26-008067.md) | [106](/filings/0001628280-26-026422.md) | [122](/filings/0001628280-26-049139.md) | [146](/filings/0001628280-26-066629.md) | | Net income | $m | [215 d](/filings/0001628280-26-008067.md) | [272](/filings/0001628280-25-019005.md) | [289](/filings/0001628280-25-035852.md) | [283](/filings/0001628280-25-045790.md) | [212 d](/filings/0001628280-26-008067.md) | [322](/filings/0001628280-26-026422.md) | [336](/filings/0001628280-26-049139.md) | [310](/filings/0001628280-26-066629.md) | [202 d](/filings/0001628280-26-008067.md) | [362](/filings/0001628280-26-026422.md) | [395](/filings/0001628280-26-049139.md) | [409](/filings/0001628280-26-066629.md) | | Diluted EPS | $ per share | not reported | [1.53](/filings/0001628280-25-019005.md) | [1.64](/filings/0001628280-25-035852.md) | [1.63](/filings/0001628280-25-045790.md) | not reported | [1.88](/filings/0001628280-26-026422.md) | [1.96](/filings/0001628280-26-049139.md) | [1.81](/filings/0001628280-26-066629.md) | not reported | [2.12](/filings/0001628280-26-026422.md) | [2.33](/filings/0001628280-26-049139.md) | [2.42](/filings/0001628280-26-066629.md) | | Basic EPS | $ per share | not reported | [1.54](/filings/0001628280-25-019005.md) | [1.64](/filings/0001628280-25-035852.md) | [1.63](/filings/0001628280-25-045790.md) | not reported | [1.88](/filings/0001628280-26-026422.md) | [1.96](/filings/0001628280-26-049139.md) | [1.81](/filings/0001628280-26-066629.md) | not reported | [2.12](/filings/0001628280-26-026422.md) | [2.33](/filings/0001628280-26-049139.md) | [2.43](/filings/0001628280-26-066629.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpenseNonoperating - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Current assets | $bn | [4.9](/filings/0001628280-25-005100.md) | [4.8](/filings/0001628280-24-017577.md) | [5.0](/filings/0001628280-24-032762.md) | [4.8](/filings/0001628280-24-043365.md) | [4.9](/filings/0001628280-26-008067.md) | [5.3](/filings/0001628280-25-019005.md) | [6.4](/filings/0001628280-25-035852.md) | [5.8](/filings/0001628280-25-045790.md) | [5.7](/filings/0001628280-26-066629.md) | [6.0](/filings/0001628280-26-026422.md) | [6.0](/filings/0001628280-26-049139.md) | [6.1](/filings/0001628280-26-066629.md) | | Total assets | $bn | [19.0](/filings/0001628280-25-005100.md) | [18.7](/filings/0001628280-25-019005.md) | [18.9](/filings/0001628280-25-035852.md) | [18.6](/filings/0001628280-25-045790.md) | [18.7](/filings/0001628280-26-008067.md) | [19.1](/filings/0001628280-26-026422.md) | [20.4](/filings/0001628280-26-049139.md) | [21.5](/filings/0001628280-26-066629.md) | [22.1](/filings/0001628280-26-066629.md) | [23.2](/filings/0001628280-26-026422.md) | [23.1](/filings/0001628280-26-049139.md) | [23.1](/filings/0001628280-26-066629.md) | | Current liabilities | $bn | [4.1](/filings/0001628280-25-005100.md) | [3.2](/filings/0001628280-24-017577.md) | [3.6](/filings/0001628280-24-032762.md) | [3.7](/filings/0001628280-24-043365.md) | [3.8](/filings/0001628280-26-008067.md) | [3.9](/filings/0001628280-25-019005.md) | [3.6](/filings/0001628280-25-035852.md) | [4.1](/filings/0001628280-25-045790.md) | [5.2](/filings/0001628280-26-066629.md) | [5.8](/filings/0001628280-26-026422.md) | [5.4](/filings/0001628280-26-049139.md) | [5.5](/filings/0001628280-26-066629.md) | | Total liabilities | $bn | [8.5](/filings/0001628280-25-005100.md) | [8.2](/filings/0001628280-24-017577.md) | [8.4](/filings/0001628280-24-032762.md) | [8.4](/filings/0001628280-24-043365.md) | [8.6](/filings/0001628280-26-008067.md) | [8.7](/filings/0001628280-25-019005.md) | [9.5](/filings/0001628280-25-035852.md) | [10.4](/filings/0001628280-25-045790.md) | [10.9](/filings/0001628280-26-066629.md) | [12.0](/filings/0001628280-26-026422.md) | [11.9](/filings/0001628280-26-049139.md) | [11.8](/filings/0001628280-26-066629.md) | | Long-term debt | $bn | [3.3](/filings/0001628280-25-005100.md) | [4.0](/filings/0001628280-24-017577.md) | [3.5](/filings/0001628280-24-032762.md) | [3.5](/filings/0001628280-24-043365.md) | [3.5](/filings/0001628280-26-008067.md) | [3.5](/filings/0001628280-25-019005.md) | [4.8](/filings/0001628280-25-035852.md) | [5.0](/filings/0001628280-25-045790.md) | [4.3](/filings/0001628280-26-066629.md) | [4.7](/filings/0001628280-26-026422.md) | [4.9](/filings/0001628280-26-049139.md) | [4.7](/filings/0001628280-26-066629.md) | | Current portion of debt | $bn | [0.8](/filings/0001628280-25-005100.md) | [0.0](/filings/0001628280-24-017577.md) | [0.5](/filings/0001628280-24-032762.md) | [0.5](/filings/0001628280-24-043365.md) | [0.5](/filings/0001628280-26-008067.md) | [0.5](/filings/0001628280-25-019005.md) | [0.0](/filings/0001628280-25-035852.md) | [0.3](/filings/0001628280-25-045790.md) | [1.3](/filings/0001628280-26-066629.md) | [1.8](/filings/0001628280-26-026422.md) | [1.7](/filings/0001628280-26-049139.md) | [1.7](/filings/0001628280-26-066629.md) | | Shareholders' equity | $bn | [10.5](/filings/0001628280-25-005100.md) | [10.5](/filings/0001628280-24-017577.md) | [10.5](/filings/0001628280-24-032762.md) | [10.3](/filings/0001628280-24-043365.md) | [10.1](/filings/0001628280-26-008067.md) | [10.4](/filings/0001628280-25-019005.md) | [10.8](/filings/0001628280-25-035852.md) | [11.0](/filings/0001628280-25-045790.md) | [11.1](/filings/0001628280-26-066629.md) | [11.1](/filings/0001628280-26-026422.md) | [11.2](/filings/0001628280-26-049139.md) | [11.3](/filings/0001628280-26-066629.md) | - Cash and equivalents: not reported - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [686 d](/filings/0001628280-26-008067.md) | [334](/filings/0001628280-25-019005.md) | [235 d](/filings/0001628280-25-035852.md) | [542 d](/filings/0001628280-25-045790.md) | [723 d](/filings/0001628280-26-008067.md) | [191](/filings/0001628280-26-026422.md) | [209 d](/filings/0001628280-26-049139.md) | [367 d](/filings/0001628280-26-066629.md) | [992 d](/filings/0001628280-26-008067.md) | [199](/filings/0001628280-26-026422.md) | [441 d](/filings/0001628280-26-049139.md) | [455 d](/filings/0001628280-26-066629.md) | | Capital expenditure | $m | [77.0 d](/filings/0001628280-26-008067.md) | [31.0](/filings/0001628280-25-019005.md) | [46.0 d](/filings/0001628280-25-035852.md) | [46.0 d](/filings/0001628280-25-045790.md) | [84.0 d](/filings/0001628280-26-008067.md) | [44.0](/filings/0001628280-26-026422.md) | [39.0 d](/filings/0001628280-26-049139.md) | [55.0 d](/filings/0001628280-26-066629.md) | [122 d](/filings/0001628280-26-008067.md) | [46.0](/filings/0001628280-26-026422.md) | [62.0 d](/filings/0001628280-26-049139.md) | [74.0 d](/filings/0001628280-26-066629.md) | | Dividends paid | $m | [31.0 d](/filings/0001628280-26-008067.md) | [36.0](/filings/0001628280-25-019005.md) | [35.0 d](/filings/0001628280-25-035852.md) | [35.0 d](/filings/0001628280-25-045790.md) | [34.0 d](/filings/0001628280-26-008067.md) | [43.0](/filings/0001628280-26-026422.md) | [44.0 d](/filings/0001628280-26-049139.md) | [43.0 d](/filings/0001628280-26-066629.md) | [43.0 d](/filings/0001628280-26-008067.md) | [53.0](/filings/0001628280-26-026422.md) | [53.0 d](/filings/0001628280-26-049139.md) | [52.0 d](/filings/0001628280-26-066629.md) | | Share repurchases | $m | [157 d](/filings/0001628280-26-008067.md) | [175](/filings/0001628280-25-019005.md) | [200 d](/filings/0001628280-25-035852.md) | [599 d](/filings/0001628280-25-045790.md) | [123 d](/filings/0001628280-26-008067.md) | [98.0](/filings/0001628280-26-026422.md) | [50.0 d](/filings/0001628280-26-049139.md) | [0.0 d](/filings/0001628280-26-066629.md) | [75.0 d](/filings/0001628280-26-008067.md) | [242](/filings/0001628280-26-026422.md) | [215 d](/filings/0001628280-26-049139.md) | [305 d](/filings/0001628280-26-066629.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: us-gaap:PaymentsOfDividendsCommonStock - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [181](/filings/0001628280-24-017577.md) | [179](/filings/0001628280-24-032762.md) | [179](/filings/0001628280-24-043365.md) | [177](/filings/0001628280-25-019005.md) | [176](/filings/0001628280-25-035852.md) | [174](/filings/0001628280-25-045790.md) | [171](/filings/0001628280-26-026422.md) | [171](/filings/0001628280-26-049139.md) | [171](/filings/0001628280-26-066629.md) | [171](/filings/0001628280-26-026422.md) | [170](/filings/0001628280-26-049139.md) | [169](/filings/0001628280-26-066629.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 167,802,384 at 2026-10-16, from the cover of the [10-Q filed 2026-10-21](/filings/0001628280-26-066629.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.